ZNTLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Zentalis Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$2.30+0.17 (+7.98%)

Close on Oct 19, 2026

Market cap: $164.05M
P/E (TTM): –
Dividend yield: –

Zentalis Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	36	37	28	46	63	56	67	25
Short-Term Investments	210	318	455	–	–	284	–	–
Cash & Short-Term Investments	246	355	483	46	63	340	67	25
Receivables	0	5.00	0	–	0.00	0.42	0.14	–
Prepaid Expenses & Other	7.30	9.98	14	15	11	6.18	1.51	–
Total Current Assets	253	386	497	452	351	345	69	–
Property, Plant & Equipment	2.77	4.70	5.82	7.71	8.15	1.10	0.50	–
Gross Property, Plant & Equipment	5.54	8.97	8.97	9.77	8.94	1.35	0.67	–
Accumulated Depreciation	-2.77	-4.27	-3.15	-2.06	-0.79	-0.25	-0.17	–
Equity Method Investments	–	0	0	21	37	0	–	–
Operating Lease Right-of-Use Assets	26	33	36	42	45	2.52	2.34	–
Goodwill	–	0	3.74	3.74	3.74	3.74	3.74	–
Intangible Assets	–	–	–	–	–	8.80	–	–
Deferred Tax Assets	0.05	0.10	0.04	–	–	–	–	–
Total Assets	289	430	552	539	455	366	87	–
Accounts Payable	7.21	7.44	15	11	12	8.66	4.29	–
Accrued Expenses	29	45	54	45	32	20	11	–
Current Portion of Leases	3.87	3.07	2.62	2.16	1.45	0.90	0.78	–
Current Income Taxes Payable	0.19	0	0.28	0.38	0.97	0.41	0	–
Total Current Liabilities	37	53	69	57	44	29	15	–
Long-Term Leases	36	40	43	45	44	1.10	–	–
Operating Lease Liabilities	40	43	46	47	46	2.00	0.78	–
Deferred Tax Liabilities	–	–	0	0.85	1.62	2.48	2.46	–
Other Long-Term Liabilities	0.50	0.85	1.78	2.62	0	1.10	1.70	–
Total Liabilities	73	93	114	105	90	32	19	–
Preferred Stock	0	0	0	0	0	0	0	–
Common Stock	0.07	0.07	0.07	0.06	0.05	0.04	0	–
Additional Paid-In Capital	1,407	1,391	1,324	1,031	724	509	0	–
Retained Earnings	-1,191	-1,054	-889	-596	-360	-201	-83	–
Comprehensive Income & Other	0.20	0.56	2.19	-1.35	-0.13	0.04	0	–
Shareholders' Equity	216	337	437	434	364	309	–	–
Noncontrolling Interest	–	0	0.11	0.22	0.53	25	6.82	7.54
Total Equity	216	337	437	434	364	333	-73	32
Total Liabilities & Equity	289	430	552	539	455	366	87	–
Shares Outstanding(shares)	69	71	71	59	45	41	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -49.5%

Financial strength

Current ratio: 4.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 65.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.14
Dividend yield: –